Výsledky vyhledávání - "Vincent Badalamenti"

Levetiracetam Pregnancy Registry: Final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations

Autor: Angela E. Scheuerle, Georgia Montouris, David Miller, Amanda Golembesky, Vincent Badalamenti, Azita Tofighy, Lewis B. Holmes, Cynthia L. Harden, John M. Thorp, Jessica Albano, Dina Battino, Chiara Pantaleoni, Torbjörn Tomson, Deborah L. Covington

Publikováno v: Birth Defects Research. 111:872-887

Background To evaluate pregnancy outcomes among women participating in the antiepileptic drug (AED) Levetiracetam Registry (LEV-Registry), and to review the impact of using two other registries' outcome definitions on the number of major congenital m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77aa93c4bf050689fb4ca7939dd991c6
https://doi.org/10.1002/bdr2.1526

Zobrazit plný text záznamu

Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies

Autor: Anyzeila Diaz, Vincent Badalamenti, Teresa Gasalla, John Whitesides, Stephan Arnold, Cindy McShea, Toufic Fakhoury

Publikováno v: Epilepsy Research. 141:73-82

Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) approved for monotherapy (in the USA) and adjunctive treatment of focal (partial-onset) seizures in adults, at a dose range of 50

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::922f69034574ac5da0b3a39406a8c20d
https://doi.org/10.1016/j.eplepsyres.2018.02.005

Zobrazit plný text záznamu

Safety and tolerability of adjunctive brivaracetam in children with focal seizures: Interim analysis of pooled data from two open-label trials

Autor: Teresa Gasalla, Anup D. Patel, Vincent Badalamenti, Jan-Peer Elshoff, Sami Elmoufti

Publikováno v: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 25

To evaluate long-term safety and tolerability of adjunctive brivaracetam (BRV) in children with epilepsy.This was an interim analysis (cut-off March 15, 2017) of pooled data from two open-label, single-arm, multicentre trials. N01263 (NCT00422422) wa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde6469ff43f747799eeee69aa0026e6
https://pubmed.ncbi.nlm.nih.gov/31810577

Zobrazit plný text záznamu

Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis

Autor: Pavel Klein, Vincent Badalamenti, John Whitesides, Teresa Gasalla, Christian Brandt

Publikováno v: Epilepsy & Behavior. 103:106864

Objective The objective of this analysis was to provide a comprehensive analysis of safety data for adjunctive brivaracetam (BRV), an antiepileptic drug (AED) of the racetam class, for treatment of focal seizures in patients with epilepsy. Methods Da

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3759dd4478854db22fc6931a8cf99dd2
https://doi.org/10.1016/j.yebeh.2019.106864

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání